Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Rating Increased to Overweight at JPMorgan Chase & Co.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was upgraded by investment analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a research note issued on Monday, Marketbeat reports.

Several other analysts also recently commented on BAYRY. Wall Street Zen raised Bayer Aktiengesellschaft from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. Zacks Research lowered Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. Finally, Morgan Stanley upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, December 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, Bayer Aktiengesellschaft presently has an average rating of “Buy”.

Bayer Aktiengesellschaft Price Performance

Shares of BAYRY opened at $9.67 on Monday. The firm has a market cap of $38.00 billion, a PE ratio of -107.43, a price-to-earnings-growth ratio of 4.90 and a beta of 0.69. Bayer Aktiengesellschaft has a 52-week low of $4.79 and a 52-week high of $10.03. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.73 and a current ratio of 1.13. The business’s 50 day moving average price is $8.21 and its two-hundred day moving average price is $7.99.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.